MarketCap
Facebook
X
Telegram
La Jolla Pharmaceutical Company EBITDA | LJPC
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA La Jolla Pharmaceutical Company
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.9 M | -33.6 M | -105 M | -190 M | -114 M | -77.6 M | -41.6 M | -21.3 M | -17.9 M | -10.7 M | -2.27 M | -3.93 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.9 M | -190 M | -49.7 M |
Quarterly EBITDA La Jolla Pharmaceutical Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -1.02 M | -2.02 M | - | 609 K | 3.85 M | 17.5 M | - | -7.37 M | -10.7 M | -9.4 M | - | -23.4 M | -26 M | -28.5 M | - | -45.1 M | -49.5 M | -49.7 M | -38.8 M | -25.6 M | -26.2 M | -23 M | -24.9 M | -20.8 M | -15.3 M | -16.4 M | -11.9 M | -10.4 M | -10.6 M | -8.96 M | -6.86 M | -5.05 M | -4.28 M | -5.13 M | - | -4.17 M | -3.16 M | -4.2 M | - | -3.45 M | -3.21 M | -671 K | - | -423 K | -904 K | -478 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.5 M | -49.7 M | -13 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Kazia Therapeutics Limited
KZIA
|
-7.74 M | $ 7.91 | 1.28 % | $ 121 M |  Australia |
 |
Fate Therapeutics
FATE
|
-135 M | $ 2.06 | -2.61 % | $ 245 M |  USA |
 |
Eton Pharmaceuticals
ETON
|
3.2 M | $ 50.15 | 0.3 % | $ 1.35 B | USA |
 |
Fulcrum Therapeutics
FULC
|
-83.4 M | $ 3.65 | -0.95 % | $ 231 M | USA |
 |
Hutchison China MediTech Limited
HCM
|
-25.9 M | $ 14.31 | -0.38 % | $ 12.3 B |  China |
 |
IDEAYA Biosciences
IDYA
|
-157 M | $ 33.2 | -4.35 % | $ 2.94 B | USA |
 |
InflaRx N.V.
IFRX
|
-44.9 M | $ 1.57 | 0.32 % | $ 106 M |  Germany |
 |
Immutep Limited
IMMP
|
-8.4 M | $ 3.07 | -4.06 % | $ 4.47 B | Australia |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-2.17 M | $ 1.89 | -6.44 % | $ 1.27 B |  Israel |
 |
Zoetis
ZTS
|
487 M | $ 80.89 | -0.17 % | $ 35.9 B | USA |
 |
Kala Pharmaceuticals
KALA
|
-38.8 M | $ 0.19 | -1.95 % | $ 1.55 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
-43.6 M | $ 0.28 | -1.99 % | $ 223 M |  Britain |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
78.8 M | $ 73.0 | -4.87 % | $ 5.42 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-90.4 M | $ 0.48 | -6.34 % | $ 5.25 K | USA |
 |
MediciNova
MNOV
|
-13.3 M | $ 1.41 | 1.44 % | $ 69.2 M | USA |
 |
Seres Therapeutics
MCRB
|
-89.8 M | $ 2.01 | -3.83 % | $ 17.8 M | USA |
 |
MediWound Ltd.
MDWD
|
-8.73 M | $ 12.1 | 0.83 % | $ 329 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-28.3 M | $ 11.35 | -1.69 % | $ 1.24 B | USA |
 |
Precigen
PGEN
|
-107 M | $ 6.05 | -2.34 % | $ 1.89 B | USA |
 |
PolyPid Ltd.
PYPD
|
-31.5 M | $ 5.3 | 0.95 % | $ 86.7 M | Israel |
 |
Rocket Pharmaceuticals
RCKT
|
-223 M | $ 2.27 | -0.87 % | $ 252 M | USA |
 |
Avidity Biosciences
RNA
|
-742 M | $ 8.04 | -1.93 % | $ 1.11 B | USA |
 |
Summit Therapeutics
SMMT
|
146 K | $ 14.5 | -6.3 % | $ 10.8 B | Britain |
 |
Celsion Corporation
CLSN
|
-14.4 M | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-14.3 M | - | -13.47 % | $ 169 M | France |
 |
Scholar Rock Holding Corporation
SRRK
|
-383 M | $ 41.71 | 0.52 % | $ 4.78 B | USA |
 |
CureVac N.V.
CVAC
|
178 M | - | - | $ 867 M | Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-11.9 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-10.1 M | - | - | $ 4.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
-8.64 M | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
-252 M | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
-107 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-100 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
Gracell Biotechnologies
GRCL
|
-566 M | - | - | $ 3.37 B | China |
 |
Galapagos NV
GLPG
|
351 M | - | - | $ 1.83 B | Belgium |
 |
Tiziana Life Sciences PLC
TLSA
|
-15.8 M | $ 0.88 | -7.06 % | $ 93.9 M | Britain |
 |
Teligent, Inc.
TLGT
|
48.6 M | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-151 M | - | - | $ 2.91 B | USA |
 |
Aphria Inc.
APHA
|
-8.68 M | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-6.22 M | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
-70.5 M | - | -6.00 % | $ 238 M | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
-43.3 M | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
17.2 M | - | 0.38 % | $ 12.9 M | Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
-26.4 T | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
-45.6 M | - | -1.68 % | $ 283 M | USA |